Cocrystal Pharma Receives Emory University Approval for CDI-988 Phase 1b Study
Cocrystal Pharma announces the approval from the Institutional Review Board, IRB, at Emory University School of Medicine to initiate a Phase 1b human challenge study with CDI-988. This study aims to evaluate CDI-988 as both a preventive and treatment for norovirus infections. Initial screening of study subjects is currently underway, with enrollment expected to begin in the first quarter of 2026. The IRB approval from Emory University School of Medicine follows Cocrystal's prior regulatory milestones, including U.S. Food and Drug Administration clearance of its investigational New Drug application.
Trade with 70% Backtested Accuracy
Analyst Views on COCP
About COCP
About the author
Cocrystal Receives IRB Approval to Initiate CDI-988 Clinical Trial, Enrollment Expected Q1 2026
- Clinical Trial Approval: Cocrystal Pharma has received approval from the Emory University Institutional Review Board to initiate a Phase 1b human challenge study for CDI-988, with enrollment expected to begin in Q1 2026, aiming to evaluate its efficacy in preventing and treating norovirus infections.
- Innovative Drug Development: CDI-988 is the first oral broad-spectrum antiviral drug specifically designed to inhibit the 3CL protease of all noroviruses, potentially revolutionizing management in high-risk environments such as hospitals and nursing homes.
- Global Health Impact: With norovirus causing approximately 700 million infections annually, Cocrystal's research addresses this significant global health challenge, which could substantially reduce cases of acute gastroenteritis and associated societal costs.
- Technological Platform Advantage: Leveraging its proprietary structure-based drug discovery platform, Cocrystal aims to rapidly develop novel antiviral agents, and the success of CDI-988 will further solidify its leadership position in the antiviral space, driving future growth for the company.
Cocrystal Pharma to Present Clinical Progress at NobleCon 21
- Conference Presentation: Cocrystal Pharma's CFO and co-CEO James Martin will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025, showcasing the latest advancements in antiviral treatments.
- Investor Participation: The conference invites interested investors and guests to attend at a discounted rate, aiming to increase visibility and engagement within the small and micro-cap market.
- Webcast Availability: A video of Cocrystal's presentation will be available on December 4 and archived for 90 days on the company's website, ensuring that investors unable to attend live can access critical information.
- Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis, leveraging unique structure-based technologies and Nobel Prize-winning expertise to create first-in-class antiviral drugs.
Cocrystal Pharma to Showcase at Noble Capital Markets Virtual Equity Conference for Emerging Growth Companies
Cocrystal Pharma Presentation: Cocrystal Pharma's CFO and co-CEO, James Martin, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025, followed by a Q&A session.
Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases like influenza and COVID, utilizing unique technologies and expertise.
Cocrystal Pharma reveals direct offering of up to $13 million.
Stock Offering Details: Cocrystal Pharma has announced a registered direct offering of 2.76 million shares at $1.70 per share, alongside a private placement of unregistered warrants for up to 5.53 million shares at an exercise price of $1.50.
Financial Projections: The company expects to raise approximately $4.7 million from the offering, with potential additional proceeds of about $8.3 million if the warrants are fully exercised.
Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
CC-42344 Antiviral Efficacy: Cocrystal Pharma's CC-42344 has demonstrated strong antiviral activity against the highly pathogenic H5N1 avian influenza strain, being approximately 1,000-fold more potent than Tamiflu, with favorable safety and tolerability in initial studies.
Concerns Over Avian Influenza Spread: The emergence of H5N1 in dairy cows has raised concerns about potential human-to-human transmission, as evidenced by confirmed human cases linked to exposure, highlighting the need for effective treatments like CC-42344.
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma's Antiviral Developments: Cocrystal Pharma is advancing its antiviral product pipeline, particularly the oral pan-viral protease inhibitor CDI-988, which has shown broad-spectrum activity against norovirus and coronaviruses. The company plans to initiate a human challenge study for CDI-988 soon, aiming to provide effective treatment options for these viral infections.
Financial Performance Overview: In the first quarter of 2025, Cocrystal reported a net loss of $2.3 million, a decrease from $4.0 million in the same period of 2024, alongside reduced research and development expenses. The company's cash reserves were noted at $6.9 million as of March 31, 2025, reflecting ongoing efforts to maintain a capital-efficient business model.
Cocrystal Receives IRB Approval to Initiate CDI-988 Clinical Trial, Enrollment Expected Q1 2026
- Clinical Trial Approval: Cocrystal Pharma has received approval from the Emory University Institutional Review Board to initiate a Phase 1b human challenge study for CDI-988, with enrollment expected to begin in Q1 2026, aiming to evaluate its efficacy in preventing and treating norovirus infections.
- Innovative Drug Development: CDI-988 is the first oral broad-spectrum antiviral drug specifically designed to inhibit the 3CL protease of all noroviruses, potentially revolutionizing management in high-risk environments such as hospitals and nursing homes.
- Global Health Impact: With norovirus causing approximately 700 million infections annually, Cocrystal's research addresses this significant global health challenge, which could substantially reduce cases of acute gastroenteritis and associated societal costs.
- Technological Platform Advantage: Leveraging its proprietary structure-based drug discovery platform, Cocrystal aims to rapidly develop novel antiviral agents, and the success of CDI-988 will further solidify its leadership position in the antiviral space, driving future growth for the company.
Cocrystal Pharma to Present Clinical Progress at NobleCon 21
- Conference Presentation: Cocrystal Pharma's CFO and co-CEO James Martin will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025, showcasing the latest advancements in antiviral treatments.
- Investor Participation: The conference invites interested investors and guests to attend at a discounted rate, aiming to increase visibility and engagement within the small and micro-cap market.
- Webcast Availability: A video of Cocrystal's presentation will be available on December 4 and archived for 90 days on the company's website, ensuring that investors unable to attend live can access critical information.
- Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis, leveraging unique structure-based technologies and Nobel Prize-winning expertise to create first-in-class antiviral drugs.
Cocrystal Pharma to Showcase at Noble Capital Markets Virtual Equity Conference for Emerging Growth Companies
Cocrystal Pharma Presentation: Cocrystal Pharma's CFO and co-CEO, James Martin, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025, followed by a Q&A session.
Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases like influenza and COVID, utilizing unique technologies and expertise.
Cocrystal Pharma reveals direct offering of up to $13 million.
Stock Offering Details: Cocrystal Pharma has announced a registered direct offering of 2.76 million shares at $1.70 per share, alongside a private placement of unregistered warrants for up to 5.53 million shares at an exercise price of $1.50.
Financial Projections: The company expects to raise approximately $4.7 million from the offering, with potential additional proceeds of about $8.3 million if the warrants are fully exercised.
Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
CC-42344 Antiviral Efficacy: Cocrystal Pharma's CC-42344 has demonstrated strong antiviral activity against the highly pathogenic H5N1 avian influenza strain, being approximately 1,000-fold more potent than Tamiflu, with favorable safety and tolerability in initial studies.
Concerns Over Avian Influenza Spread: The emergence of H5N1 in dairy cows has raised concerns about potential human-to-human transmission, as evidenced by confirmed human cases linked to exposure, highlighting the need for effective treatments like CC-42344.
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma's Antiviral Developments: Cocrystal Pharma is advancing its antiviral product pipeline, particularly the oral pan-viral protease inhibitor CDI-988, which has shown broad-spectrum activity against norovirus and coronaviruses. The company plans to initiate a human challenge study for CDI-988 soon, aiming to provide effective treatment options for these viral infections.
Financial Performance Overview: In the first quarter of 2025, Cocrystal reported a net loss of $2.3 million, a decrease from $4.0 million in the same period of 2024, alongside reduced research and development expenses. The company's cash reserves were noted at $6.9 million as of March 31, 2025, reflecting ongoing efforts to maintain a capital-efficient business model.
